Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Adenosine triphosphate–Tosyl-L-arginine methyl ester (ATP–TAME) ternary complex is a supramolecular chemical assembly formed through non-covalent interactions between ATP and the synthetic arginine derivative TAME. This complex is primarily studied in the context of physical chemistry and molecular recognition to model how arginine residues in proteins interact with the phosphate and adenine moieties of ATP (Galan et al., J. Am. Chem. Soc.). The interaction typically involves electrostatic attraction and bidentate hydrogen bonding between the guanidinium group of TAME and the polyphosphate chain of ATP, alongside potential pi-stacking interactions. As noted in the target name, this is a non-therapeutic interaction, meaning it is a laboratory-observed chemical phenomenon rather than a biological pathway or receptor involved in disease. Consequently, it does not serve as a target for pharmacological intervention, and there are no drugs or clinical applications associated with it.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine triphosphate–Tosyl-L-arginine methyl ester ternary complex (ATP–TAME–ATP).